254 related articles for article (PubMed ID: 32792852)
1.
Shahid M; Kim M; Jin P; Zhou B; Wang Y; Yang W; You S; Kim J
Int J Biol Sci; 2020; 16(14):2490-2505. PubMed ID: 32792852
[TBL] [Abstract][Full Text] [Related]
2. Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target.
Jung JH; You S; Oh JW; Yoon J; Yeon A; Shahid M; Cho E; Sairam V; Park TD; Kim KP; Kim J
Cancer Lett; 2018 Nov; 437():1-12. PubMed ID: 30145203
[TBL] [Abstract][Full Text] [Related]
3. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway.
Tsai TF; Lin JF; Lin YC; Chou KY; Chen HE; Ho CY; Chen PC; Hwang TI
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31341011
[TBL] [Abstract][Full Text] [Related]
5. Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer.
Krafft U; Tschirdewahn S; Hess J; Harke NN; Hadaschik B; Olah C; Krege S; Nyirády P; Szendröi A; Szücs M; Módos O; Székely E; Reis H; Szarvas T
Urol Oncol; 2019 Nov; 37(11):810.e7-810.e15. PubMed ID: 31053526
[TBL] [Abstract][Full Text] [Related]
6. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
[TBL] [Abstract][Full Text] [Related]
7. Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer.
Ryu H; Jin H; Ho JN; Bae J; Lee E; Lee SE; Lee S
Biol Pharm Bull; 2019; 42(1):66-72. PubMed ID: 30606990
[TBL] [Abstract][Full Text] [Related]
8. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
9. LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling.
Chen J; Li Y; Li Z; Cao L
J Biochem Mol Toxicol; 2020 Apr; 34(4):e22452. PubMed ID: 32052927
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of cisplatin resistance in bladder cancer.
Drayton RM; Catto JW
Expert Rev Anticancer Ther; 2012 Feb; 12(2):271-81. PubMed ID: 22316374
[TBL] [Abstract][Full Text] [Related]
11. Diverse Roles of Protein Palmitoylation in Cancer Progression, Immunity, Stemness, and Beyond.
Li M; Zhang L; Chen CW
Cells; 2023 Sep; 12(18):. PubMed ID: 37759431
[TBL] [Abstract][Full Text] [Related]
12. Proteomic profiling of S-acylated macrophage proteins identifies a role for palmitoylation in mitochondrial targeting of phospholipid scramblase 3.
Merrick BA; Dhungana S; Williams JG; Aloor JJ; Peddada S; Tomer KB; Fessler MB
Mol Cell Proteomics; 2011 Oct; 10(10):M110.006007. PubMed ID: 21785166
[TBL] [Abstract][Full Text] [Related]
13. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
14. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms.
Li F; Zheng Z; Chen W; Li D; Zhang H; Zhu Y; Mo Q; Zhao X; Fan Q; Deng F; Han C; Tan W
Drug Resist Updat; 2023 May; 68():100938. PubMed ID: 36774746
[TBL] [Abstract][Full Text] [Related]
15. LncRNA-MALAT1 mediates cisplatin resistance via miR-101-3p/VEGF-C pathway in bladder cancer.
Liu P; Li X; Cui Y; Chen J; Li C; Li Q; Li H; Zhang X; Zu X
Acta Biochim Biophys Sin (Shanghai); 2019 Nov; 51(11):1148-1157. PubMed ID: 31650173
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin.
Wang X; Zhang F; Wu XR
Sci Rep; 2017 Apr; 7():45983. PubMed ID: 28378811
[TBL] [Abstract][Full Text] [Related]
17. JUND-dependent up-regulation of HMOX1 is associated with cisplatin resistance in muscle-invasive bladder cancer.
Peng Y; Chen Y; Chen S; Wang J; Jiang C; Hou W; Xu C
J Biochem; 2020 Jul; 168(1):73-82. PubMed ID: 32240302
[TBL] [Abstract][Full Text] [Related]
18. Fatty Acid Synthase Promotes the Palmitoylation of Chikungunya Virus nsP1.
Zhang N; Zhao H; Zhang L
J Virol; 2019 Feb; 93(3):. PubMed ID: 30404808
[TBL] [Abstract][Full Text] [Related]
19. Insulin-regulated protein palmitoylation impacts endothelial cell function.
Wei X; Song H; Semenkovich CF
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):346-54. PubMed ID: 24357059
[TBL] [Abstract][Full Text] [Related]
20. Detection of protein palmitoylation in cultured hippocampal neurons by immunoprecipitation and acyl-biotin exchange (ABE).
Brigidi GS; Bamji SX
J Vis Exp; 2013 Feb; (72):. PubMed ID: 23438969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
